MedImmune Inks Exclusive License Agreement with La Jolla Institute for Asthma Discovery
March 04, 2009
MedImmune Inks Exclusive License Agreement with La Jolla Institute for Asthma Discovery
By Ben Butkus
If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.